Helus Pharma announced progress in its clinical programs for mental health treatments, with topline Phase 3 data for HLP003, a potential adjunctive therapy for major depressive disorder, expected in Q4 2026. The company also plans to start a Phase 2 monotherapy study for HLP004 targeting generalized anxiety disorder in Q1 2027. HLP003 has FDA Breakthrough Therapy Designation, potentially speeding its review, and Helus aims to file for FDA approval in 2028. These developments highlight Helus Pharma’s focus on addressing unmet needs in depression and anxiety treatment with novel serotonergic agonists.
Helus Pharma's clinical program updates provide context for readers following health-sector stocks. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 22, 2026 03:02 WIB: Among 150 priced US health-sector stocks, 73 rose and 75 fell. DexCom (DXCM) traded at USD 79.99 with a 1-day decline of 6.71% and 100% sell order activity, contrasting with Tango Therapeutics (TNGX) at USD 26.93 gaining 6.67% with 99% buy orders, while Canopy Growth (CGC) was priced at USD 0.67, down 6.67% but with 100% buy orders and a typical hold time of 39 days on Pluang.
National Healthcare Properties (NHP) announced that Lindsay Gordon, its Executive Vice President and Head of Senior Housing, has been elected to the executive board of the American Senior Housing Association (ASHA). ASHA is a leading national organiz...
Akzo Nobel reported Q3 2026 earnings with revenue of $2.85 billion and EPS of $0.38, both below analyst estimates of $2.96 billion and $0.42 respectively. Despite these misses, the company's core profit exceeded expectations, indicating underlying st...
United Airlines reported a strong third-quarter revenue of $17.9 billion, up 17.4% year-over-year, and provided optimistic guidance for the fourth quarter. Jefferies raised its price target for United Airlines stock to $142 from $134, suggesting a 36...
OFG Bancorp reported third-quarter earnings per share of $1.33, surpassing analyst estimates of around $1.23. However, its revenue came in slightly below expectations at $185.7 million versus estimates near $187 million. The earnings beat was driven ...
SEI Investments is set to report its Q3 2026 earnings on October 21 after market close, with analysts projecting earnings per share of $1.59 and revenue of $658.54 million. These estimates indicate a strong year-over-year growth of 22.3% in earnings ...
